文献速递神经肿瘤

MiR-198通过靶向MGMT增强胶质母细胞瘤对替莫唑胺的敏感性

MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
PubMed 文献 · J Neurooncol · 2017-04-19

研究显示胶质母细胞瘤标本中miR-198水平大幅下调,且其低表达与患者不良预后相关;miR-198过表达在体外和体内均增加对替莫唑胺的化疗敏感性,MGMT被鉴定为miR-198的直接靶点,miR-198过表达阻止MGMT蛋白翻译,而MGMT过表达可恢复miR-198诱导的替莫唑胺化疗敏感性。

要点

  • 胶质母细胞瘤标本中miR-198水平大幅下调,低表达与患者不良预后相关。
  • miR-198过表达在体外和体内均增加对替莫唑胺的化疗敏感性。
  • MGMT是miR-198的直接靶点,miR-198过表达阻止MGMT蛋白翻译。

核心结论

  • MiR-198通过靶向MGMT诱导胶质母细胞瘤的化疗敏感性,未来可能作为胶质母细胞瘤的新诊断标志物和治疗靶点。

研究设计与样本

  • 研究检测了胶质母细胞瘤标本中miR-198水平,并在体外和体内进行miR-198过表达实验,鉴定MGMT为直接靶点。

主要发现

  • 胶质母细胞瘤标本中miR-198水平大幅下调,且miR-198表达降低与胶质母细胞瘤患者不良预后相关。
  • miR-198过表达在体外和体内均增加对替莫唑胺的化疗敏感性。
  • MGMT被鉴定为miR-198的直接靶点,miR-198过表达阻止MGMT的蛋白翻译。
  • MGMT过表达可恢复miR-198诱导的替莫唑胺化疗敏感性。
  • 临床胶质母细胞瘤标本中MGMT蛋白水平上调,并与miR-198水平呈负相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma is one of the most frequent and aggressive brain tumors. Accumulating evidence indicates that microRNAs are involved in glioma proliferation, invasion and drug resistance. Previous studies showed that miR-198 is downregulated in glioblastoma. However, the function of miR-198 in glioblastoma is still unclear. In this study, we report that miR-198 levels were greatly downregulated in glioblastoma specimens and decreased expression of miR-198 was associated with poor prognosis in patients with glioblastoma. And overexpression of miR-198 increased chemosensitivity to temozolomide in vitro and in vivo. O6-methylguanine-DNA methyltransferase (MGMT) was identified as a direct target of miR-198, and miR-198 overexpression prevented the protein translation of MGMT. Furthermore, overexpression of MGMT restored miR-198-induced chemosensitivity to temozolomide. Moreover, the protein levels of MGMT were upregulated in clinical glioblastoma specimens and inversely correlated with miR-198 levels. In conclusion, our studies revealed that MiR-198 induces chemosensitivity in glioblastoma by targeting MGMT and that miR-198 may be used as a new diagnostic marker and therapeutic target for glioblastoma in the future.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nie E, Jin X, Wu W, et al. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. J Neurooncol. 2017. PMID: 28425046. doi:10.1007/s11060-017-2425-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。